e-learning
resources
Paris 2018
Sunday, 16.09.2018
Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Patients eligible for anti-IL-5/anti-IL-5Ra treatment in a cohort of adult-onset asthma
P. Ilmarinen (Seinäjoki, Finland), L. Tuomisto (Seinäjoki, Finland), O. Niemelä (Seinäjoki, Finland), H. Kankaanranta (Seinäjoki and Tampere, Finland)
Source:
International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Session:
Role of IgE and interleukin (IL)-5 in Th2-cell signatures
Session type:
Thematic Poster
Number:
1130
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Ilmarinen (Seinäjoki, Finland), L. Tuomisto (Seinäjoki, Finland), O. Niemelä (Seinäjoki, Finland), H. Kankaanranta (Seinäjoki and Tampere, Finland). Patients eligible for anti-IL-5/anti-IL-5Ra treatment in a cohort of adult-onset asthma. 1130
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Osteoporosis onset in patients prescribed ICS for COPD: matched cohort study
Source: International Congress 2018 – Interdependence of COPD and comorbidities and the underlying mechanisms
Year: 2018
Patients at risk for COPD compared to patients diagnosed with COPD
Source: Annual Congress 2009 - Epidemiology of COPD
Year: 2009
A longitudinal follow-up of severe asthma patients receiving reslizumab
Source: International Congress 2017 – Asthma management
Year: 2017
Depressive symptoms among patients with chronic obstructive pulmonary disease before and after smoking cessation – a Danish nationwide cohort study of 21 184 patients
Source: Virtual Congress 2020 – Comorbidities/multimorbidites and mortality in patients with chronic lung diseases
Year: 2020
Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Frequency and impact of bronchiectasis in a cohort of patients in a COPD clinic
Source: International Congress 2017 – Highlights on clinical problems in COPD
Year: 2017
Re-evaluation of asthma diagnosis in patients with adult-onset asthma
Source: International Congress 2017 – New research in asthma and COPD
Year: 2017
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Effect of asthma exacerbation during pregnancy in women with asthma: a population-based cohort study
Source: Eur Respir J, 55 (2) 1901335; 10.1183/13993003.01335-2019
Year: 2020
“App” for uncontrolled moderate-severe asthma patients follow-up
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Prognosis of COPD according to exacerbation history: a population-based cohort study
Source: International Congress 2019 – COPD: epidemiology and spirometry
Year: 2019
Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study
Source: Eur Respir J, 54 (5) 1900804; 10.1183/13993003.00804-2019
Year: 2019
Characteristics and outcomes of chronic cough in individuals with asthma: a population-based study
Source: International Congress 2018 – Asthma and allergy in adults and children and their biomarkers
Year: 2018
Long-term prognosis of new adult-onset asthma in obese patients
Source: Eur Respir J, 57 (4) 2001209; 10.1183/13993003.01209-2020
Year: 2021
Two therapy option in patients with uncontrolled asthma
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Efficacy of ruzam in the treatment of patients with mild-to-moderate asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004
Population-based case-finding to identify subjects with undiagnosed asthma or COPD
Source: Eur Respir J, 55 (6) 2000024; 10.1183/13993003.00024-2020
Year: 2020
Anti-inflammatory asthma therapy adherence in paediatric patients: The PACMAN cohort study
Source: Annual Congress 2010 - Management of airway disease
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept